Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers
- Stéfane Raynaud
- Nadine Carbuccia
- Carole Colin
- José Adélaïde
- Marie-Joelle Mozziconacci
- Philippe Metellus
- Olivier Chinot
- Daniel Birnbaum
- Max Chaffanet
- Dominique Figarella-Branger
- Corresponding author:
- Max Chaffanet [ firstname.lastname@example.org ]
Published online on: Wednesday, September 1, 2010
- Pages: 883-884 DOI: 10.3892/ol_00000156
Somatic mutations of isocitrate dehydrogenase (IDH)-1 and IDH2 proteins have been described in gliomas. The mutations target the R132 amino acid residue in IDH1 and the R172 residue in IDH2, both of which are encoded by the fourth exon of the corresponding gene (1). Mutations of IDH1 are frequent (>80%) in astrocytomas and oligodendrogliomas, whereas they are very rare in primary glioblastomas and other tumors of the nervous system (2,3). IDH2 mutations are rare, but more common in oligodendroglial tumors, as compared to astrocytomas. These mutations are also mutually exclusive with those in IDH1. IDH mutations occur at the substrate binding site and inactivate the standard enzymatic activity (4).
Recently, the same mutations, which are considered to be rare in the majority of common tumors outside gliomas (5,6), were discovered in acute myeloid leukemias (AMLs) with normal karyotype (7,8). In malignant myeloid diseases, a new mutation affecting R140 in IDH2 was detected (9,10). Authors of this study (unpublished data), as well as other investigators (8,9), determined that the R140Q substitution was the most frequent IDH mutation in these pathologies. Thus, mutations of IDH1 and IDH2 were found in 28% of primary AMLs.
Materials and methods
Exons 4 of IDH1 and IDH2 were analyzed on panels of DNAs from randomly chosen brain and breast cancer samples. Their sizes were approximately the same as our set of AMLs previously reported (unpublished data). For tumors of the nervous system, the set comprised 48 low-grade gliomas (5 astrocytomas, 22 oligoastrocytomas and 21 oligodendrogliomas) and 58 primary glioblastomas. The breast cancer panel comprised 94 samples, including 60 invasive ductal carcinomas, 7 invasive lobular carcinomas, 4 medullary carcinomas, 5 mixed type, 1 tubular carcinoma, 3 others and 14 not informed.
DNA sequencing of IDH1, IDH2 exons 4 was performed. Briefly, purified PCR products (1 μl) were used for sequencing using the Big Dye terminator v1.1 kit (Applied Biosystems), including the forward or reverse primer. After G50 purification, sequences were loaded on an ABI 3130XL automat (Applied Biosystems). The sequence data files were analyzed using SeqScape and Phred/Phrap/Consed softwares. Mutations were confirmed on an independent PCR product.
We investigated whether the IDH2 R140 new mutation was present in tumors of the nervous system and may have been overlooked. We also aimed to determine whether breast cancers exhibited any IDH2 mutation. We determined the sequence of exon 4 of IDH1 and IDH2 genes from the DNA of brain and breast tumor samples.
In low-grade gliomas, we found 31 IDH1 mutations (~65%) affecting residue 132 and distributed as follows: 28 R132H, 2 R132C and 1 R132S. IDH2 was mutated in only 1 case (not mutated for IDH1) at residue 172 (R172M). In primary glioblastomas, only 2 IDH1 heterozygous mutations (R132H) were noted, but no IDH2 mutation. No IDH1 or IDH2 mutations were found in the 94 breast cancer samples.
The frequency of IDH1 and IDH2 mutations in our panel of gliomas is similar to what has previously been reported (2,3). Despite this high frequency, the IDH2 R140 residue was not affected in our series of neural tumors. Compared to hematopoietic diseases, the IDH2 R172 mutation was also more rare and the IDH1 mutations more prominent in tumors of the nervous system (Table I). IDH mutations were completely absent in breast tumors, as previously noted (5,6). However, no previous study investigated the IDH2 mutation in breast cancer. Our study showed that this disease is not associated with the IDH2 mutation. Thus, the IDH2 R140 mutation appears to currently be restricted to hematopoietic diseases. All IDH arginine mutants produce 2-hydroxyglutarate (8,10). The specific role of the R140 mutation in hematopoietic diseases remains to be established, but may be linked to subtle enzymatic differences between allele mutants.
This study was supported by Inserm, Institut Paoli-Calmettes and by institutional grants to CRO2. Frozen samples were provided by the AP-HM TumorBank (Authorization no. 2008-70).
Hartmann C, Meyer J, Balss J, et al: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 118:469–474. 2009. View Article : Google Scholar : PubMed/NCBI
Bleeker FE, Lamba S, Leenstra S, et al: IDH1 mutations at residue p. R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat. 30:7–11. 2009. View Article : Google Scholar : PubMed/NCBI
Gross S, Cairns RA, Minden MD, et al: Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 207:339–344. 2010. View Article : Google Scholar
Ward PS, Patel J, Wise DR, et al: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 17:1–10. 2010.PubMed/NCBI